Access the full text.
Sign up today, get DeepDyve free for 14 days.
Peter Meyer, Katharina Landgraf, B. Högel, W. Eiermann, B. Ataseven (2012)BRCA2 Mutations and Triple-Negative Breast Cancer
PLoS ONE, 7
P. Mote, J. Leary, K. Avery, K. Sandelin, G. Chenevix-Trench, J. Kirk, C. Clarke (2004)Germ‐line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen‐responsive proteins and the predominance of progesterone receptor A
R. Dent, E. Warner (2007)Screening for hereditary breast cancer.
Seminars in oncology, 34 5
O. Metzger-Filho, A. Tutt, E. Azambuja, K. Saini, G. Viale, S. Loi, I. Bradbury, J. Bliss, H. Azim, P. Ellis, A. Leo, J. Baselga, C. Sotiriou, M. Piccart-Gebhart (2012)Dissecting the heterogeneity of triple-negative breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 15
A. Veronesi, C. Giacomi, M. Magri, D. Lombardi, M. Zanetti, C. Scuderi, R. Dolcetti, A. Viel, D. Crivellari, E. Bidoli, M. Boiocchi (2005)Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases
BMC Cancer, 5
G. Palomba, M. Pisano, A. Cossu, M. Budroni, M. Dedola, A. Farris, A. Contu, P. Baldinu, F. Tanda, G. Palmieri (2005)Spectrum and prevalence of BRCA1 and BRCA2 germline mutations in Sardinian patients with breast carcinoma through hospital‐based screening
A. Wright, A. Carothers, M. Pirastu (1999)Population choice in mapping genes for complex diseases
Nature Genetics, 23
Foulkes (2010)Triple-negative breast cancer
N Engl J Med, 363
Budroni (2007)Cancer incidence in Sassari Province (1998–2002)
M. Casula, M. Colombino, M. Satta, A. Cossu, A. Lissia, M. Budroni, E. Simeone, R. Calemma, C. Loddo, C. Caracò, N. Mozzillo, A. Daponte, G. Comella, S. Canzanella, M. Guida, G. Castello, P. Ascierto, G. Palmieri (2007)Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
European journal of cancer, 43 1
(1970)Cancer Incidence in Five Continents
B. Peshkin, M. Alabek, C. Isaacs (2010)BRCA1/2 mutations and triple negative breast cancers.
Breast disease, 32 1-2
C. Meads, I. Ahmed, R. Riley (2012)A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance
Breast Cancer Research and Treatment, 132
A. Musolino, M. Bella, B. Bortesi, M. Michiara, N. Naldi, P. Zanelli, M. Capelletti, D. Pezzuolo, R. Camisa, M. Savi, T. Neri, A. Ardizzoni (2007)BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Breast, 16 3
E. Rakha, J. Reis-Filho, F. Baehner, D. Dabbs, T. Decker, V. Eusebi, S. Fox, S. Ichihara, J. Jacquemier, S. Lakhani, J. Palacios, A. Richardson, S. Schnitt, F. Schmitt, P. Tan, G. Tse, S. Badve, I. Ellis (2010)Breast cancer prognostic classification in the molecular era: the role of histological grade
Breast Cancer Research : BCR, 12
D. Ford, D. Easton, Michael Stratton, S. Narod, D. Goldgar, P. Devilee, D. Bishop, B. Weber, G. Lenoir, J. Chang-Claude, H. Sobol, M. Teare, J. Struewing, A. Arason, S. Scherneck, J. Peto, T. Rebbeck, P. Tonin, S. Neuhausen, R. Barkardottir, J. Eyfjord, H. Lynch, B. Ponder, S. Gayther, J. Birch, A. Lindblom, D. Stoppa-Lyonnet, Y. Bignon, Å. Borg, U. Hamann, N. Haites, Rodney Scott, C. Maugard, H. Vasen, S. Seitz, L. Cannon-Albright, A. Schofield, M. Zelada-Hedman (1998)Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
American journal of human genetics, 62 3
(2005)patients through a hospital - based screening
G. Palomba, A. Cossu, E. Friedman, M. Budroni, A. Farris, A. Contu, M. Pisano, P. Baldinu, M. Sini, F. Tanda, G. Palmieri (2007)Origin and distribution of the BRCA2-8765delAG mutation in breast cancer
BMC Cancer, 7
Debra Winkeljohn (2008)Triple-negative breast cancer.
Clinical journal of oncology nursing, 12 6
M. Arcos-Burgos, M. Arcos-Burgos, M. Muenke (2002)Genetics of population isolates
Clinical Genetics, 61
C. Thibault, W. Khodari, M. Lequoy, J. Gligorov, Y. Belkacemi (2013)HER2 status for prognosis and prediction of treatment efficacy in adenocarcinomas: a review.
Critical reviews in oncology/hematology, 88 1
L. Fuksa, S. Mičuda, J. Grim, A. Ryška, H. Hornychová (2012)Predictive Biomarkers in Breast Cancer: Their Value in Neoadjuvant Chemotherapy
Cancer Investigation, 30
G. Palomba, A. Loi, A. Uras, P. Fancello, G. Piras, A. Gabbas, A. Cossu, M. Budroni, A. Contu, F. Tanda, A. Farris, S. Orrù, C. Floris, M. Pisano, M. Lovicu, M. Santona, G. Landriscina, L. Crisponi, G. Palmieri, M. Monne (2009)A role of BRCA1 and BRCA2 germline mutations in breast cancer susceptibility within Sardinian population
BMC Cancer, 9
G. Palomba, M. Colombino, A. Contu, B. Massidda, G. Baldino, A. Pazzola, M. Ionta, F. Capelli, V. Trova, T. Sedda, G. Sanna, F. Tanda, M. Budroni, G. Palmieri, A. Cossu (2012)Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
Journal of Translational Medicine, 10
Germline mutations in BRCA1 or BRCA2 genes have been demonstrated to increase the risk of developing breast cancer. Among the prognostic factors currently used in clinical practice, the disease stage and the receptor status play a crucial role in the management of breast carcinoma. Triple‑negative breast cancer (TNBC) has been classified as a disease subgroup that is negative for oestrogen, progesterone and HER2 receptor expression, and presents a poor prognosis. The present study investigated the correlation between BRCA1/2 mutations and TNBC status in a large series (n=726) of breast cancer patients from Sardinia. The BRCA mutation screening was performed on genomic DNA from peripheral blood samples by denaturing high‑performance liquid chromatography analysis and automated DNA sequencing. Overall, 21/726 (2.9%) patients carried a germline mutation in BRCA1 or BRCA2. The TNBC phenotype was significantly associated with the BRCA1 mutations (P<0.001), whereas no association was found with the BRCA2 mutations (P=0.837). With respect to patient origin within Sardinia, a significant inverse distribution of mutations was found; BRCA1 and BRCA2 mutations represented 86 and 93% of the mutated cases in Southern and Middle‑Northern Sardinia, respectively (P<0.001). Patients from the geographical area with BRCA1 mutation prevalence presented a TNBC incidence much higher than that observed in cases from the area with BRCA2 mutation prevalence (12 vs. 4%, respectively; P=0.037). These findings further confirmed that the occurrence of TNBC is significantly associated with the BRCA1 mutation carrier status and that a different ‘genetic background’ may have a phenotypic impact in the onset of breast cancer.
Oncology Letters – Spandidos Publications
Published: Apr 1, 2014
Access the full text.
Sign up today, get DeepDyve free for 14 days.